HC Wainwright Expects Higher Earnings for Lyell Immunopharma

Lyell Immunopharma, Inc. (NASDAQ:LYEL) – HC Wainwright lifted their Q1 2025 earnings estimates for shares of Lyell Immunopharma in a research note issued on Thursday, March 13th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.17) per share for the quarter, up from their prior forecast of ($0.20). HC Wainwright currently has a “Neutral” rating and a $1.00 target price on the stock. The consensus estimate for Lyell Immunopharma’s current full-year earnings is ($0.78) per share. HC Wainwright also issued estimates for Lyell Immunopharma’s Q2 2025 earnings at ($0.18) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.20) EPS and FY2025 earnings at ($0.73) EPS.

Lyell Immunopharma Trading Down 11.7 %

Shares of NASDAQ LYEL opened at $0.52 on Monday. The business has a 50-day moving average of $0.62 and a 200-day moving average of $0.90. The firm has a market capitalization of $152.66 million, a price-to-earnings ratio of -0.65 and a beta of -0.41. Lyell Immunopharma has a 12 month low of $0.51 and a 12 month high of $3.15.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The business had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%.

Institutional Investors Weigh In On Lyell Immunopharma

Several hedge funds have recently bought and sold shares of the stock. Decheng Capital LLC bought a new position in shares of Lyell Immunopharma in the 4th quarter worth $7,622,000. Foresite Capital Management V LLC purchased a new position in Lyell Immunopharma in the fourth quarter worth $5,205,000. venBio Partners LLC bought a new position in Lyell Immunopharma in the fourth quarter valued at $4,545,000. Geode Capital Management LLC raised its position in Lyell Immunopharma by 2.9% during the fourth quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company’s stock valued at $2,648,000 after purchasing an additional 117,303 shares in the last quarter. Finally, State Street Corp lifted its stake in Lyell Immunopharma by 1.9% during the third quarter. State Street Corp now owns 3,889,553 shares of the company’s stock worth $5,368,000 after purchasing an additional 71,233 shares during the last quarter. 66.05% of the stock is currently owned by institutional investors.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.